All In Biotech

Drug Trial Radar · NCT02051946

Novel Drug Delivery Technique Via Retroject Device

Novel Drug Delivery Technique for Glaucoma Patients

Last checked: Nov 20, 2026Latest source record: Feb 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

9

Actual

Start

May 2014

Primary completion

Oct 2015

Study completion Oct 2015

Sponsor

Lead sponsor
Molly WalshAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 31, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to identify whether or not injection of a study drug (ethacrynic acid) using the investigational Retroject device is able to lower eye pressures in patients with advanced glaucoma. 20 patients with advanced glaucoma with visual acuity less than 20/200 and intraocular pressures (IOP) \>20mmHg on maximum medical therapy will be asked to participate in the study. The first five patients will have the Retroject device placed over their eye for 30 seconds and then removed. Assuming no issues, then it will be placed on the eye for one minute. The second group of patients (3 total) will have the Retroject device placed on the eye and then an injection of ethacrynic acid into the episcleral vein. The third group of patients (12 total) will have the Retroject device placed on the eye and then will be randomized in a 2:1 ratio to receive either an ethacrynic acid injection or a balanced salt solution injection. All 20 patients will then return for intraocular pressure measurements on days 1, 2, 3, and 7 as well as 6 weeks after injection. In addition, the patients will undergo pre and post intervention corneal endothelial assessments (endothelial cell count, shape analysis, and pachymetry). Potential safety issues are unlikely and include bleeding, infection, pain, ototoxicity, or temporary or permanent loss of vision.

Conditions

  • Glaucoma

Interventions

  • Retroject DeviceDevice

  • ethacrynic acid injectionDrug

  • balanced salt solutionDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Intraocular pressures (IOP) lowering effectTime frame: Days 1, 2, 3, and 7, and 6 weeks after injection

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Duke University Eye Center

    Durham, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.